| Identification | Back Directory | [Name]
QNZ-46 | [CAS]
1237744-13-6 | [Synonyms]
QNZ46
QNZ-46
QNZ 46
CS-2059
CS-2438
QNZ 46;QNZ-46
QNZ-46;QNZ 46;QNZ46
QNZ46 - CAS 1237744-13-6 - Calbiochem
4-[6-Methoxy-2-[(1E)-2-(3-nitrophenyl)ethenyl]-4-oxo-3(4H)-quinazolinyl]-benzoic Acid
Benzoic acid, 4-[6-methoxy-2-[(1E)-2-(3-nitrophenyl)ethenyl]-4-oxo-3(4H)-quinazolinyl]- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C24H17N3O6 | [MDL Number]
MFCD22666391 | [MOL File]
1237744-13-6.mol | [Molecular Weight]
443.41 |
| Chemical Properties | Back Directory | [Melting point ]
>260 °C | [Boiling point ]
705.8±70.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO: soluble5mg/mL (warmed; clear solution) | [form ]
Yellow powder | [pka]
4.28±0.10(Predicted) | [color ]
white to beige | [InChI]
InChI=1S/C24H17N3O6/c1-33-19-10-11-21-20(14-19)23(28)26(17-8-6-16(7-9-17)24(29)30)22(25-21)12-5-15-3-2-4-18(13-15)27(31)32/h2-14H,1H3,(H,29,30)/b12-5+ | [InChIKey]
GNLVJIICVWDSNI-LFYBBSHMSA-N | [SMILES]
C(O)(=O)C1=CC=C(N2C(=O)C3=C(N=C2/C=C/C2=CC=CC([N+]([O-])=O)=C2)C=CC(OC)=C3)C=C1 |
| Hazard Information | Back Directory | [Uses]
QZN-46 is a known antagonist, or non-selective inhibitor, for NDMA-selective glutamate receptors. | [Biological Activity]
QNZ46 is a noncompetitive inhibitor of GluN2C/D containing NMDA receptors. KD and IC50 values for binding and inhibition of GluN1/Glun2D receptors by QNZ46 are 4.9 and 3.9 μMrespectively. QNZ46 does not compete for binding of glutamate or glycinebut QNZ46 receptor binding requires the binding of glutamate to the GluN2 subunit. | [in vivo]
Ischemic stroke model: QNZ46 (20 mg/kg; i.p.; single administration) significantly reduces brain lesion volume and improved neurological function in transient middle cerebral artery occlusion (tMCAO) mice[2].
EAE model: QNZ46 (2 mg/kg+1 mg/kg CP465022; i.p.; once a day for 28 days) significantly reduces clinical scores in experimental autoimmune encephalomyelitis (EAE) mice and protected small-diameter myelinated axons in the spinal cord[3].
| Animal Model: | C57BL/6 mice (male, 25-30 g, 8-12 weeks) + transient middle cerebral artery occlusion (tMCAO)[2] | | Dosage: | 20 mg/kg (50% DMSO/β-cyclodextrin) | | Administration: | Single i.p. injection 120 min prior to ischemia | | Result: | Reduced infarct volume by 68%, preserved myelinated axons in the external capsule, and improved neurological performance. |
| Animal Model: | Animal Model:
.
C57BL/6 mice (female, 20-22 g, 8-12 weeks) + experimental autoimmune encephalomyelitis (EAE)[3] | | Dosage: |
2 mg/kg QNZ46 + 1 mg/kg CP465022 (0.5% methyl cellulose) | | Administration: | Daily i.p. injections from day 0 to day 28 post-immunization | | Result: | Combined QNZ46/CP465022 treatment reduced clinical severity and preserved small-diameter myelinated axons in spinal cord. |
| [IC 50]
NMDA Receptor | [storage]
room temperature |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|